ELVN Company Profile and Key Details

Enliven Therapeutics, Inc. has 59.24 million shares outstanding. The public float is 36.32 million shares, elevated short interest at 12.28% of float. This equals 5.08 million shares. The short ratio is 11.7 days. Institutional investors hold 112.22% of the float. Insiders own 8.88%. RA CAPITAL MANAGEMENT, L.P. holds 2.12 million shares, Leonard Braden Michael has 1.77 million shares and COMMODORE CAPITAL LP has 1.45 million shares. Over the past six months, insider transactions show net selling. They sold 273.54 thousand shares across 20 transactions.

Enliven Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.74. This means the shares are trading above this model’s fair value.

Enliven Therapeutics, Inc. generated EPS of -$1.85 over the past year. Five-year average earnings growth is 19.02%. Wall Street analysts project EPS growth of -15.94% annually over the next five years. The latest quarter delivered EPS of -$0.38. The next quarter is forecast at -$0.39. Next year's EPS is expected at -$14.98. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $59.00 to $37.00. The high target offers 49.03% upside. The low target suggests -6.54% downside. The mean target is $49.50. This offers 25.03% upside. Enliven Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -13.64%. The prior quarter beat by 14.29%. Over the last six quarters, Apple has recorded several small beats. These include -13.21% in March 13, 2025.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) closed at $41.91 USD, gaining $2.32 (5.86%) from the previous close of $39.59. The stock is currently mid-range between its 52-week high and low $14.79 and $48.53. With a market capitalization of about $2.55 billion, Enliven Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.45). Key stats such as the average daily volume over the past year has been around 1.10 million shares, volume is running light vs its 52-week average. Headquartered in Boulder, CO, Enliven Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard A. Fair, the company employs approximately 62 people and listed since March 12, 2020. Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

Our AI price prediction model suggests that Enliven Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.58%, with price expected at $35.40 by May 25, 2026, within a range of $33.27 to $37.46 3-Month Outlook: Projected rise of 85.83%, reaching $73.57 by August 07, 2026, with a range of $73.02 to $74.02. 1-Year Outlook: Projected gain of 10.81%, with price at $43.87 by May 11, 2027, within a range of $42.21 to $45.81.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares are up 75.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Enliven Therapeutics, Inc. trading at a premium to the broader market with a P/E of -25.26. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $42.15, suggesting 6.47% upside. Our AI forecast model points to short-term weakness (-10.58% over two weeks), a medium-term rise (85.83% over three months), and a longer-term gain (10.81% over one year), with expected trading ranges indicating moderate volatility.

Enliven Therapeutics, Inc. trades at a P/E ratio of -25.26, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.5 trading at moderately above to book value. The P/FCF stands at -36.89, also below market averages.